# Ebola vaccine trial begins in DR Congo as outbreak kills 2,500

> Half of all deaths occurred in the last 20 days. The outbreak, caused by the rare Bundibugyo species, is now the deadliest in the country's history.

_Source: Multiple independent sources · 2026-08-22 · 5 min read · Verified against primary sources_

Canonical: https://iyu.app/e/ebola-dr-congo-vaccine-trial

## The 60-second version

DR Congo's Ebola outbreak has killed 2,500 — half in the last 20 days. A vaccine trial is beginning, but the outbreak is growing exponentially.

**Key points**

- The outbreak is caused by the rare Bundibugyo Ebola species, first identified in Uganda in 2007.
- Half of all deaths occurred in the last 20 days, indicating the outbreak is accelerating.
- A vaccine trial using a modified Ervebo platform is starting in affected regions.
- Conflict, displacement, and infrastructure challenges in eastern DRC are hampering the response.

**Verdict.** The vaccine trial offers hope, but the outbreak is outpacing the response. Without rapid international support, this could become the deadliest Ebola outbreak in history.

## Full explainer

> **⚑ Caveat:** The death toll and infection figures are WHO-reported as of August 22, 2026. Outbreak conditions change rapidly.


### The crisis — 2,500 dead, half in the last 20 days

The Democratic Republic of Congo is facing its deadliest Ebola outbreak on record. More than **2,500 people** have died since the outbreak was declared on May 15, 2026. Alarmingly, half of those deaths occurred in the last 20 days — a sign that the outbreak is accelerating, not slowing.

- **2,500+** — Deaths since May 15, 2026
- **50%** — Of deaths occurred in the last 20 days
- **Bundibugyo** — Rare Ebola species causing the outbreak

The outbreak is caused by the **Bundibugyo species** of Ebola — a rarer strain than the Zaire ebolavirus that caused the 2014-2016 West Africa epidemic. Bundibugyo was first identified in Uganda in 2007 and has a lower historical fatality rate, but this outbreak has proven unusually severe.


### The response — Vaccine trial begins

A vaccine trial is now starting in the affected regions, using a modified version of the **Ervebo vaccine** that proved highly effective against Zaire ebolavirus. The trial will test whether the same vaccine platform — a recombinant vesicular stomatitis virus (rVSV) vector — can protect against the Bundibugyo species.

The WHO has warned that the outbreak is **growing exponentially** and that the speed of infections is outpacing containment measures. Health workers are deploying treatment centers, safe burial teams, and contact tracing, but the outbreak is concentrated in conflict-affected areas of eastern DRC where displacement camps and limited infrastructure make response extremely difficult.


### The challenge — Why this outbreak is so hard to stop

Several factors make this outbreak particularly challenging. The affected region is home to large displaced populations living in camps, where social distancing and hygiene measures are difficult to maintain. The area is also affected by armed conflict, which has disrupted health infrastructure and limited access for response teams.

Community mistrust — worsened by past outbreaks and political instability — has also led to some resistance to public health measures. Health workers have faced hostility in some areas, and safe burial practices have been difficult to implement.


### The bottom line — What this means

The DRC Ebola outbreak is a test of the global health infrastructure built after the 2014-2016 West Africa epidemic. The vaccine trial is a critical step, but it's racing against a virus that's moving faster than the response. The coming weeks will determine whether the outbreak can be contained or whether it will become the deadliest Ebola event in history.


## Primary sources

- [BBC News](https://www.bbc.com/search?q=Ebola+Congo+2026)
- [AP News](https://apnews.com/hub/ebola-outbreak)
- [WHO](https://www.who.int/emergencies/disease-outbreak-news)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._